Seven studies (439 systemic sclerosis cases, 274 controls) were included in the meta-analysis, indicating lower circulating adiponectin levels in systemic sclerosis patients (standardized mean difference = −0.16, p = 0.07); however, the decrease was statistically significant in diffuse cutaneous systemic sclerosis (p = 0.003) but not limited cutaneous systemic sclerosis (p = 0.81) subgroup. Here, ADIPOQ is linked to limited cutaneous systemic sclerosis.